The Indenoisoquinoline Noncamptothecin Topoisomerase I Inhibitors: Update and Perspectives

Overview

Journal Mol Cancer Ther

Date 2009 Apr 23

PMID 19383846

Citations 79

Authors

Yves Pommier

Mark Cushman

Affiliations

Soon will be listed here.

Abstract

Because camptothecins are effective against previously resistant tumors and are the only class of topoisomerase I (Top1) inhibitors approved for cancer treatment, we developed the indenoisoquinolines. Like camptothecins, the indenoisoquinolines selectively trap Top1-DNA cleavage complexes and have been cocrystallized with the Top1-DNA cleavage complexes. Indenoisoquinolines show antitumor activity in animal models. They have several advantages over the camptothecins: (a) They are synthetic and chemically stable. (b) The Top1 cleavage sites trapped by the indenoisoquinolines have different genomic locations, implying differential targeting of cancer cell genomes. (c) The Top1 cleavage complexes trapped by indenoisoquinolines are more stable, indicative of prolonged drug action. (d) They are seldom or not used as substrates for the multidrug resistance efflux pumps (ABCG2 and MDR-1). Among the >400 indenoisoquinolines synthesized and evaluated, three have been retained as leads for clinical development by the National Cancer Institute: NSC 706744, NSC 725776 (Indimitecan), and NSC 724998 (Indotecan). The trapping of Top1 cleavage complexes by indenoisoquinolines in cells results in the rapid and sustained phosphorylation of histone H2AX (γ-H2AX). We discuss the use of γ-H2AX as a pharmacodynamic biomarker for the clinical development of the indenoisoquinolines.

Citing Articles

Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.

Waitkus M, Erman E, Reitman Z, Ashley D Neuro Oncol. 2024; 26(6):1012-1024.

PMID: 38285162 PMC: 11145458. DOI: 10.1093/neuonc/noae016.

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents.

Yakkala P, Penumallu N, Shafi S, Kamal A Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895927 PMC: 10609717. DOI: 10.3390/ph16101456.

Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex.

Sun Y, Baechler S, Zhang X, Kumar S, Factor V, Arakawa Y Nat Commun. 2023; 14(1):3762.

PMID: 37353483 PMC: 10290057. DOI: 10.1038/s41467-023-39374-9.

Identification of multidentate tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors that simultaneously access the DNA, protein and catalytic-binding sites by oxime diversification.

Zhao X, Wang W, Lountos G, Kiselev E, Tropea J, Needle D RSC Chem Biol. 2023; 4(5):334-343.

PMID: 37181631 PMC: 10170656. DOI: 10.1039/d2cb00230b.

Mechanism of action of non-camptothecin inhibitor Genz-644282 in topoisomerase I inhibition.

Nishida M, Terabayashi T, Matsuoka S, Okuma T, Adachi S, Tomo T Commun Biol. 2022; 5(1):982.

PMID: 36114357 PMC: 9481636. DOI: 10.1038/s42003-022-03920-w.

References

Miao Z, Player A, Shankavaram U, Wang Y, Zimonjic D, Lorenzi P . Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res. 2007; 67(18):8752-61. DOI: 10.1158/0008-5472.CAN-06-4554. View

Urasaki Y, Laco G, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C . Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res. 2001; 61(5):1964-9. View

Xiao X, Cushman M . An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes. J Am Chem Soc. 2005; 127(28):9960-1. PMC: 2526349. DOI: 10.1021/ja042485n. View

Tamura H, Kohchi C, Yamada R, Ikeda T, Koiwai O, Patterson E . Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res. 1991; 19(1):69-75. PMC: 333535. DOI: 10.1093/nar/19.1.69. View

Fox B, Xiao X, Antony S, Kohlhagen G, Pommier Y, Staker B . Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids. J Med Chem. 2003; 46(15):3275-82. DOI: 10.1021/jm0300476. View

Van H, Le Q, Lee K, Lee E, Kwon Y, Kim T . Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex. Bioorg Med Chem Lett. 2007; 17(21):5763-7. DOI: 10.1016/j.bmcl.2007.08.062. View

Antony S, Jayaraman M, Laco G, Kohlhagen G, Kohn K, Cushman M . Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res. 2003; 63(21):7428-35. View

Nagarajan M, Morrell A, Antony S, Kohlhagen G, Agama K, Pommier Y . Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors. J Med Chem. 2006; 49(17):5129-40. DOI: 10.1021/jm060046o. View

Pommier Y . Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6(10):789-802. DOI: 10.1038/nrc1977. View

10.

Morrell A, Jayaraman M, Nagarajan M, Fox B, Meckley M, Ioanoviciu A . Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay. Bioorg Med Chem Lett. 2006; 16(16):4395-9. DOI: 10.1016/j.bmcl.2006.05.048. View

11.

Sirikantaramas S, Yamazaki M, Saito K . Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants. Proc Natl Acad Sci U S A. 2008; 105(18):6782-6. PMC: 2365566. DOI: 10.1073/pnas.0801038105. View

12.

Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C . Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999; 59(23):5938-46. View

13.

Cho W, Le Q, Van H, Lee K, Kang B, Lee E . Design, docking, and synthesis of novel indeno[1,2-c]isoquinolines for the development of antitumor agents as topoisomerase I inhibitors. Bioorg Med Chem Lett. 2007; 17(13):3531-4. DOI: 10.1016/j.bmcl.2007.04.064. View

14.

Xiao X, Antony S, Pommier Y, Cushman M . Total synthesis and biological evaluation of 22-hydroxyacuminatine. J Med Chem. 2006; 49(4):1408-12. PMC: 2532531. DOI: 10.1021/jm051116e. View

15.

Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y . Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A. 1987; 84(16):5565-9. PMC: 298903. DOI: 10.1073/pnas.84.16.5565. View

16.

Xiao X, Antony S, Pommier Y, Cushman M . On the binding of indeno[1,2-c]isoquinolines in the DNA-topoisomerase I cleavage complex. J Med Chem. 2005; 48(9):3231-8. DOI: 10.1021/jm050017y. View

17.

Fujimori A, Hoki Y, Popescu N, Pommier Y . Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. Oncol Res. 1996; 8(7-8):295-301. View

18.

Pommier Y, Cherfils J . Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol Sci. 2005; 26(3):138-45. DOI: 10.1016/j.tips.2005.01.008. View

19.

Antony S, Kohlhagen G, Agama K, Jayaraman M, Cao S, Durrani F . Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol Pharmacol. 2004; 67(2):523-30. DOI: 10.1124/mol.104.003889. View

20.

Xiao X, Cushman M . Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment. J Org Chem. 2005; 70(23):9584-7. DOI: 10.1021/jo0513360. View